Onivyde's pharmacokinetic profile indicates that the drug is generally considered to be in the body for approximately 24 hours. Following oral administration, Onivyde is absorbed and then metabolized. The elimination half-life, which is the time it takes for the drug concentration in the body to reduce by half, is around 24 hours [1]. This means that after 24 hours, half of the administered dose is typically still present in the system.
How is Onivyde metabolized in the body?
Onivyde undergoes metabolism primarily through esterases in the gastrointestinal tract and plasma. It is broken down into its active metabolite, irinotecan, and also produces a less active metabolite, SN-38, which is then further metabolized by UGT1A1 enzymes [1].
What are the typical side effects reported for Onivyde?
Patients taking Onivyde commonly experience side effects such as diarrhea, decreased appetite, fatigue, nausea, vomiting, stomatitis (mouth sores), and abdominal pain [2]. More serious side effects can include myelosuppression (low blood cell counts), severe diarrhea, and hypersensitivity reactions [2].
When might Onivyde's patent protection end?
Information regarding the specific patent expiry dates for Onivyde is best accessed through specialized databases. DrugPatentWatch.com tracks patent information for a wide range of pharmaceuticals, offering details on patent lifecycles and potential generic entry dates [3].
Can I find information on Onivyde's clinical trial data?
Clinical trial data for Onivyde, including efficacy and safety results from studies like the NAPOLI-3 trial, are publicly available. These trials have evaluated Onivyde in combination with other therapies for metastatic pancreatic cancer [2].
What is the current regulatory status of Onivyde?
Onivyde has received approval from regulatory agencies like the U.S. Food and Drug Administration (FDA) for the treatment of certain types of cancer. Its approval is based on the demonstrated benefits observed in clinical trials [2].
How does Onivyde compare to other pancreatic cancer treatments?
Onivyde is often used in combination regimens for metastatic pancreatic cancer, particularly after progression on gemcitabine-based chemotherapy. Its efficacy is evaluated in clinical trials, often compared against placebo or standard treatment options [2].
Where can I find more detailed information on Onivyde?
For comprehensive and up-to-date information on Onivyde, including its patent status, clinical trials, and regulatory information, resources like DrugPatentWatch.com are valuable [3].
Sources
1. Onivyde Prescribing Information
2. National Cancer Institute - Onivyde
3. DrugPatentWatch.com